{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T20:58:00Z","timestamp":1792270680333,"version":"4.4.0"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,2,27]],"date-time":"2025-02-27T00:00:00Z","timestamp":1740614400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,2,27]],"date-time":"2025-02-27T00:00:00Z","timestamp":1740614400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1038\/s41591-025-03538-5","type":"journal-article","created":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T12:47:23Z","timestamp":1740746843000},"page":"1547-1556","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Cerebrospinal fluid circulating tumor DNA profiling for risk stratification and matched treatment of central nervous system metastases"],"prefix":"10.1038","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3493-7139","authenticated-orcid":false,"given":"Mei-Mei","family":"Zheng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0478-176X","authenticated-orcid":false,"given":"Qing","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua-Jun","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ben-Yuan","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4870-4408","authenticated-orcid":false,"given":"Li-Bo","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guang-Ling","family":"Jie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hai-Yan","family":"Tu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5105-6421","authenticated-orcid":false,"given":"Si-Yang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4302-9332","authenticated-orcid":false,"given":"Jia-Tao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fa-Man","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin-Ji","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4138-8115","authenticated-orcid":false,"given":"Xu-Chao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Zhao","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4945-5631","authenticated-orcid":false,"given":"Yi","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin-Chao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong-Hong","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Bang","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi-Hong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chong-Rui","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Su-Yun","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Si-Yang Maggie","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5063-5712","authenticated-orcid":false,"given":"Shang-Li","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guo-Qiang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong-Qin","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-1372-4418","authenticated-orcid":false,"given":"Yang-Si","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3611-0258","authenticated-orcid":false,"given":"Yi-Long","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,27]]},"reference":[{"key":"3538_CR1","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1016\/j.jtho.2023.06.017","volume":"18","author":"CS Gillespie","year":"2023","unstructured":"Gillespie, C. S. et al. Genomic alterations and the incidence of brain metastases in advanced and metastatic non-small cell lung cancer: a systematic review and meta-analysis. J. Thorac. Oncol. 18, 1703\u20131713 (2023).","journal-title":"J. Thorac. Oncol."},{"key":"3538_CR2","doi-asserted-by":"crossref","first-page":"1962","DOI":"10.1016\/j.jtho.2016.06.029","volume":"11","author":"YS Li","year":"2016","unstructured":"Li, Y. S. et al. Leptomeningeal metastases in patients with NSCLC with EGFR mutations. J. Thorac. Oncol. 11, 1962\u20131969 (2016).","journal-title":"J. Thorac. Oncol."},{"key":"3538_CR3","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/j.jtho.2019.01.007","volume":"14","author":"MM Zheng","year":"2019","unstructured":"Zheng, M. M. et al. Clinical utility of cerebrospinal fluid cell-free DNA as liquid biopsy for leptomeningeal metastases in ALK-rearranged NSCLC. J. Thorac. Oncol. 14, 924\u2013932 (2019).","journal-title":"J. Thorac. Oncol."},{"key":"3538_CR4","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1001\/jamaoncol.2016.3834","volume":"3","author":"PW Sperduto","year":"2017","unstructured":"Sperduto, P. W. et al. Estimating survival in patients With lung cancer and brain metastases: an update of the graded prognostic assessment for lung cancer using molecular markers (lung-molGPA). JAMA Oncol. 3, 827\u2013831 (2017).","journal-title":"JAMA Oncol."},{"key":"3538_CR5","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms9839","volume":"6","author":"L De Mattos-Arruda","year":"2015","unstructured":"De Mattos-Arruda, L. et al. Cerebrospinal fluid-derived circulating tumour DNA better represents the genomic alterations of brain tumours than plasma. Nat. Commun. 6, 8839 (2015).","journal-title":"Nat. Commun."},{"key":"3538_CR6","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1158\/2159-8290.CD-21-1486","volume":"12","author":"JT Zhang","year":"2022","unstructured":"Zhang, J. T. et al. Longitudinal undetectable molecular residual disease defines potentially cured population in localized non-small cell lung cancer. Cancer Discov 12, 1690\u20131701 (2022).","journal-title":"Cancer Discov"},{"key":"3538_CR7","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1016\/j.ccell.2023.09.007","volume":"41","author":"Y Pan","year":"2023","unstructured":"Pan, Y. et al. Dynamic circulating tumor DNA during chemoradiotherapy predicts clinical outcomes for locally advanced non-small cell lung cancer patients. Cancer Cell 41, 1763\u20131773 (2023).","journal-title":"Cancer Cell"},{"key":"3538_CR8","doi-asserted-by":"crossref","first-page":"e2120040","DOI":"10.1001\/jamanetworkopen.2021.20040","volume":"4","author":"MD White","year":"2021","unstructured":"White, M. D. et al. Detection of leptomeningeal disease using cell-fee DNA From cerebrospinal fluid. JAMA Netw. Open 4, e2120040 (2021).","journal-title":"JAMA Netw. Open"},{"key":"3538_CR9","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.1200\/JCO.2016.66.6487","volume":"34","author":"EI Pentsova","year":"2016","unstructured":"Pentsova, E. I. et al. Evaluating cancer of the central nervous system through next-generation sequencing of cerebrospinal fluid. J. Clin. Oncol. 34, 2404\u20132415 (2016).","journal-title":"J. Clin. Oncol."},{"key":"3538_CR10","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1038\/s41586-019-0882-3","volume":"565","author":"AM Miller","year":"2019","unstructured":"Miller, A. M. et al. Tracking tumour evolution in glioma through liquid biopsies of cerebrospinal fluid. Nature 565, 654\u2013658 (2019).","journal-title":"Nature"},{"key":"3538_CR11","doi-asserted-by":"crossref","first-page":"4015","DOI":"10.1093\/brain\/awad195","volume":"146","author":"G Berzero","year":"2023","unstructured":"Berzero, G., Pieri, V., Mortini, P., Filippi, M. & Finocchiaro, G. The coming of age of liquid biopsy in neuro-oncology. Brain 146, 4015\u20134024 (2023).","journal-title":"Brain"},{"key":"3538_CR12","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1038\/nature22364","volume":"545","author":"C Abbosh","year":"2017","unstructured":"Abbosh, C. et al. Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution. Nature 545, 446\u2013451 (2017).","journal-title":"Nature"},{"key":"3538_CR13","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1038\/s41586-023-05776-4","volume":"616","author":"C Abbosh","year":"2023","unstructured":"Abbosh, C. et al. Tracking early lung cancer metastatic dissemination in TRACERx using ctDNA. Nature 616, 553\u2013562 (2023).","journal-title":"Nature"},{"key":"3538_CR14","doi-asserted-by":"crossref","first-page":"iv84","DOI":"10.1093\/annonc\/mdx221","volume":"28","author":"E Le Rhun","year":"2017","unstructured":"Le Rhun, E. et al. EANO-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up of patients with leptomeningeal metastasis from solid tumours. Ann. Oncol. 28, iv84\u2013iv99 (2017).","journal-title":"Ann. Oncol."},{"key":"3538_CR15","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1038\/s41588-020-0592-7","volume":"52","author":"D Shih","year":"2020","unstructured":"Shih, D. et al. Genomic characterization of human brain metastases identifies drivers of metastatic lung adenocarcinoma. Nat. Genet. 52, 371\u2013377 (2020).","journal-title":"Nat. Genet."},{"key":"3538_CR16","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1093\/annonc\/mdy009","volume":"29","author":"YS Li","year":"2018","unstructured":"Li, Y. S. et al. Unique genetic profiles from cerebrospinal fluid cell-free DNA in leptomeningeal metastases of EGFR-mutant non-small-cell lung cancer: a new medium of liquid biopsy. Ann. Oncol. 29, 945\u2013952 (2018).","journal-title":"Ann. Oncol."},{"key":"3538_CR17","doi-asserted-by":"crossref","first-page":"2353","DOI":"10.1038\/s41591-022-02047-z","volume":"28","author":"J Jee","year":"2022","unstructured":"Jee, J. et al. Overall survival with circulating tumor DNA-guided therapy in advanced non-small-cell lung cancer. Nat. Med. 28, 2353\u20132363 (2022).","journal-title":"Nat. Med."},{"key":"3538_CR18","doi-asserted-by":"crossref","first-page":"3535","DOI":"10.1002\/cncr.32372","volume":"125","author":"H Wang","year":"2019","unstructured":"Wang, H. et al. Genes associated with increased brain metastasis risk in non-small cell lung cancer: comprehensive genomic profiling of 61 resected brain metastases versus primary non-small cell lung cancer (Guangdong Association Study of Thoracic Oncology 1036). Cancer 125, 3535\u20133544 (2019).","journal-title":"Cancer"},{"key":"3538_CR19","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-023-40793-x","volume":"14","author":"A Skakodub","year":"2023","unstructured":"Skakodub, A. et al. Genomic analysis and clinical correlations of non-small cell lung cancer brain metastasis. Nat. Commun. 14, 4980 (2023).","journal-title":"Nat. Commun."},{"key":"3538_CR20","doi-asserted-by":"crossref","first-page":"224r","DOI":"10.1126\/scitranslmed.3007094","volume":"6","author":"C Bettegowda","year":"2014","unstructured":"Bettegowda, C. et al. Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci. Transl. Med. 6, 224r (2014).","journal-title":"Sci. Transl. Med."},{"key":"3538_CR21","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1038\/s41571-022-00660-y","volume":"19","author":"A Tivey","year":"2022","unstructured":"Tivey, A., Church, M., Rothwell, D., Dive, C. & Cook, N. Circulating tumour DNA\u2014looking beyond the blood. Nat. Rev. Clin. Oncol. 19, 600\u2013612 (2022).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"3538_CR22","doi-asserted-by":"crossref","DOI":"10.2217\/cns-2018-0015","volume":"8","author":"DE Piccioni","year":"2019","unstructured":"Piccioni, D. E. et al. Analysis of cell-free circulating tumor DNA in 419 patients with glioblastoma and other primary brain tumors. CNS Oncol. 8, CNS34 (2019).","journal-title":"CNS Oncol."},{"key":"3538_CR23","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1200\/JCO.21.01626","volume":"40","author":"AC Tan","year":"2022","unstructured":"Tan, A. C. & Tan, D. Targeted therapies for lung cancer patients with oncogenic driver molecular alterations. J. Clin. Oncol. 40, 611\u2013625 (2022).","journal-title":"J. Clin. Oncol."},{"key":"3538_CR24","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.lungcan.2015.01.020","volume":"88","author":"D Rangachari","year":"2015","unstructured":"Rangachari, D. et al. Brain metastases in patients with EGFR-mutated or ALK-rearranged non-small-cell lung cancers. Lung Cancer 88, 108\u2013111 (2015).","journal-title":"Lung Cancer"},{"key":"3538_CR25","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.jbmt.2013.02.002","volume":"17","author":"B Chikly","year":"2013","unstructured":"Chikly, B. & Quaghebeur, J. Reassessing cerebrospinal fluid (CSF) hydrodynamics: a literature review presenting a novel hypothesis for CSF physiology. J. Bodyw. Mov. Ther. 17, 344\u2013354 (2013).","journal-title":"J. Bodyw. Mov. Ther."},{"key":"3538_CR26","volume":"7","author":"M Li","year":"2022","unstructured":"Li, M. et al. Utilizing phenotypic characteristics of metastatic brain tumors to improve the probability of detecting circulating tumor DNA from cerebrospinal fluid in non-small-cell lung cancer patients: development and validation of a prediction model in a prospective cohort study. ESMO Open 7, 100305 (2022).","journal-title":"ESMO Open"},{"key":"3538_CR27","volume":"20","author":"M Li","year":"2022","unstructured":"Li, M. et al. Dynamic monitoring of cerebrospinal fluid circulating tumor DNA to identify unique genetic profiles of brain metastatic tumors and better predict intracranial tumor responses in non-small cell lung cancer patients with brain metastases: a prospective cohort study (GASTO 1028). BMC Med. 20, 398 (2022).","journal-title":"BMC Med."},{"key":"3538_CR28","first-page":"1","volume":"42","author":"EQ Lee","year":"2022","unstructured":"Lee, E. Q., Camidge, D. R. & Mehta, G. Extending our reach: expanding enrollment in brain metastases and primary brain tumor clinical trials. Am. Soc. Clin. Oncol. Educ. Book 42, 1\u20139 (2022).","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"3538_CR29","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1038\/s41591-023-02461-x","volume":"29","author":"SM Liu","year":"2023","unstructured":"Liu, S. M. et al. First-line pyrotinib in advanced HER2-mutant non-small-cell lung cancer: a patient-centric phase 2 trial. Nat. Med. 29, 2079\u20132086 (2023).","journal-title":"Nat. Med."},{"key":"3538_CR30","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1007\/s11060-021-03789-5","volume":"153","author":"GU Mehta","year":"2021","unstructured":"Mehta, G. U. et al. US Food and Drug Administration regulatory updates in neuro-oncology. J. Neuro-Oncol. 153, 375\u2013381 (2021).","journal-title":"J. Neuro-Oncol."},{"key":"3538_CR31","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1016\/j.ccell.2021.09.012","volume":"39","author":"A Liu","year":"2021","unstructured":"Liu, A. et al. Serial assessment of measurable residual disease in medulloblastoma liquid biopsies. Cancer Cell 39, 1519\u20131530 (2021).","journal-title":"Cancer Cell"},{"key":"3538_CR32","volume":"12","author":"SM Prakadan","year":"2021","unstructured":"Prakadan, S. M. et al. Genomic and transcriptomic correlates of immunotherapy response within the tumor microenvironment of leptomeningeal metastases. Nat. Commun. 12, 5955 (2021).","journal-title":"Nat. Commun."},{"key":"3538_CR33","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1158\/2159-8290.CD-14-1129","volume":"5","author":"PK Paik","year":"2015","unstructured":"Paik, P. K. et al. Next-generation sequencing of stage IV squamous cell lung cancers reveals an association of PI3K aberrations and evidence of clonal heterogeneity in patients with brain metastases. Cancer Discov. 5, 610\u2013621 (2015).","journal-title":"Cancer Discov."},{"key":"3538_CR34","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1212\/WNL.0b013e3181dc1a69","volume":"74","author":"JL Clarke","year":"2010","unstructured":"Clarke, J. L., Perez, H. R., Jacks, L. M., Panageas, K. S. & Deangelis, L. M. Leptomeningeal metastases in the MRI era. Neurology 74, 1449\u20131454 (2010).","journal-title":"Neurology"},{"key":"3538_CR35","doi-asserted-by":"crossref","first-page":"5480","DOI":"10.1158\/1078-0432.CCR-17-0047","volume":"23","author":"BY Jiang","year":"2017","unstructured":"Jiang, B. Y. et al. Detection of driver and resistance mutations in leptomeningeal metastases of NSCLC by next-generation sequencing of cerebrospinal fluid circulating tumor cells. Clin. Cancer Res. 23, 5480\u20135488 (2017).","journal-title":"Clin. Cancer Res."},{"key":"3538_CR36","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.cell.2022.01.003","volume":"185","author":"B Nguyen","year":"2022","unstructured":"Nguyen, B. et al. Genomic characterization of metastatic patterns from prospective clinical sequencing of 25,000 patients. Cell 185, 563\u2013575 (2022).","journal-title":"Cell"},{"key":"3538_CR37","doi-asserted-by":"crossref","first-page":"102238","DOI":"10.1016\/j.eclinm.2023.102238","volume":"64","author":"LS Maggie","year":"2023","unstructured":"Maggie, L. S. et al. Efficacy, safety and dose selection of AZD3759 in patients with untreated EGFR-mutated non-small-cell lung cancer and central nervous system metastases in China (CTONG1702-Arm 8): a multi-center, single-arm, phase 2 trial. eCinicalMedicine 64, 102238 (2023).","journal-title":"eCinicalMedicine"},{"key":"3538_CR38","doi-asserted-by":"crossref","first-page":"e353","DOI":"10.1016\/j.cllc.2022.03.014","volume":"23","author":"Q Zhou","year":"2022","unstructured":"Zhou, Q. et al. Safety and efficacy of epitinib for EGFR-mutant non-small cell lung cancer with brain metastases: open-label multicentre dose-expansion phase Ib study. Clin. Lung Cancer 23, e353\u2013e361 (2022).","journal-title":"Clin. Lung Cancer"},{"key":"3538_CR39","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1016\/j.ccell.2021.07.005","volume":"39","author":"Q Zhou","year":"2021","unstructured":"Zhou, Q. et al. Bevacizumab plus erlotinib in Chinese patients with untreated, EGFR-mutated, advanced NSCLC (ARTEMIS-CTONG1509): a multicenter phase 3 study. Cancer Cell 39, 1279\u20131291 (2021).","journal-title":"Cancer Cell"},{"key":"3538_CR40","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/S2213-2600(24)00171-1","volume":"12","author":"JJ Yang","year":"2024","unstructured":"Yang, J. J. et al. Foritinib in advanced ROS1-rearranged non-small-cell lung cancer in China: a multicentre, open-label, single-arm, phase 2 study. Lancet Respir. Med. 12, 671\u2013680 (2024).","journal-title":"Lancet Respir. Med."},{"key":"3538_CR41","doi-asserted-by":"crossref","first-page":"S14","DOI":"10.1016\/j.annonc.2021.01.047","volume":"32","author":"H Chen","year":"2021","unstructured":"Chen, H. et al. 32O first-in-human (FIH) study of SCC244, a novel potent and highly selective c- MET inhibitor, in patients (pts) with advanced non-small cell lung cancer (NSCLC). Ann. Oncol. 32, S14 (2021).","journal-title":"Ann. Oncol."},{"key":"3538_CR42","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1038\/s41587-021-00857-z","volume":"39","author":"IW Deveson","year":"2021","unstructured":"Deveson, I. W. et al. Evaluating the analytical validity of circulating tumor DNA sequencing assays for precision oncology. Nat. Biotechnol. 39, 1115\u20131128 (2021).","journal-title":"Nat. Biotechnol."},{"key":"3538_CR43","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.jtho.2020.10.008","volume":"16","author":"MM Zheng","year":"2021","unstructured":"Zheng, M. M. et al. Genotyping of cerebrospinal fluid associated with osimertinib response and resistance for leptomeningeal metastases in EGFR-mutated NSCLC. J. Thorac. Oncol. 16, 250\u2013258 (2021).","journal-title":"J. Thorac. Oncol."},{"key":"3538_CR44","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.cell.2018.03.057","volume":"173","author":"S Turajlic","year":"2018","unstructured":"Turajlic, S. et al. Tracking cancer evolution reveals constrained routes to metastases: TRACERx renal. Cell 173, 581\u2013594 (2018).","journal-title":"Cell"},{"key":"3538_CR45","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1038\/nmeth.2883","volume":"11","author":"A Roth","year":"2014","unstructured":"Roth, A. et al. PyClone: statistical inference of clonal population structure in cancer. Nat. Methods 11, 396\u2013398 (2014).","journal-title":"Nat. Methods"},{"key":"3538_CR46","doi-asserted-by":"crossref","first-page":"e1004416","DOI":"10.1371\/journal.pcbi.1004416","volume":"11","author":"N Niknafs","year":"2015","unstructured":"Niknafs, N., Beleva-Guthrie, V., Naiman, D. Q. & Karchin, R. SubClonal hierarchy inference from somatic mutations: automatic reconstruction of cancer evolutionary trees from multi-region next generation sequencing. PLoS Comput. Biol. 11, e1004416 (2015).","journal-title":"PLoS Comput. Biol."},{"key":"3538_CR47","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1093\/bioinformatics\/btq706","volume":"27","author":"KP Schliep","year":"2011","unstructured":"Schliep, K. P. phangorn: phylogenetic analysis in R. Bioinformatics 27, 592\u2013593 (2011).","journal-title":"Bioinformatics"},{"key":"3538_CR48","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.annonc.2023.04.514","volume":"34","author":"D Boiarsky","year":"2023","unstructured":"Boiarsky, D. et al. Molecular markers of metastatic disease in KRAS-mutant lung adenocarcinoma. Ann. Oncol. 34, 589\u2013604 (2023).","journal-title":"Ann. Oncol."}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41591-025-03538-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-025-03538-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-025-03538-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,20]],"date-time":"2025-05-20T14:59:15Z","timestamp":1747753155000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41591-025-03538-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,27]]},"references-count":48,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["3538"],"URL":"https:\/\/doi.org\/10.1038\/s41591-025-03538-5","relation":{},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,27]]},"assertion":[{"value":"17 November 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Q.Z. declares honoraria from AstraZeneca, Boehringer Ingelheim, BMS, Eli Lilly, MSD, Pfizer, Roche and Sanofi outside the submitted work. W.Z.Z. declares honoraria from AstraZeneca, BMS, MSD, Roche and Innovent outside the submitted work. Y.L.W. declares: advisory services for AstraZeneca, Boehringer Ingelheim, Novartis and Takeda; speaker fees from AstraZeneca, Beigene, Boehringer Ingelheim, BMS, Eli Lilly, MSD, Pfizer, Roche and Sanofi; and grants from AstraZeneca, Boehringer Ingelheim, BMS, Hengrui and Roche outside the submitted work. The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}